Biogen has released data show that treatment with its flagship multiple sclerosis therapies – Tecfidera and Tysabri – may improve outcomes for sufferers if used early in the course of the disease.
Sterile injectable medicines specialist Fresenius Kabi has agreed to acquire Akorn, a US manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for $4.3 billion.
Outsourcing services provider PCI Pharma Services (PCI) has significantly expanded its serialisation capability.
Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month – the lowest injectable biologic psoriasis treatment currently on the market.
In a new snapshot survey of leading pharmaceutical businesses in the UK, companies have said that changes to the way the National Institute for Health & Care Excellence (NICE) and NHS England (NHSE) assess new medicines will decrease access to the latest treatments, with new medicines for cancer set to be impacted the most.
UK patients will benefit from access to the most cost-effective treatments nearly 5 months faster after changes to the NICE drug evaluation process were approved.
Vaccines and antibodies could be transported and stored without refrigeration by capturing them in tiny silica ‘cages’, a discovery which could make getting vital medicines to remote or dangerous places much easier, cheaper and safer.
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul injection in Europe, the Middle East and North Africa.
Regeneron Pharmaceuticals and Sanofi have gained US FDA approval for the companies’ new supplemental Biologics License Application for a once-monthly, 300 mg dose of Praluent Injection for adults with high low-density lipoprotein cholesterol.
Boston-based biopharma company, Paratek Pharmaceuticals, has entered into collaboration with Zai Lab to develop and commercialise of omadacycline for patients in China.